To test our hypothesis that increased TYMP expression in CRC tumors restrains adoptive dendritic cell therapy efficacy by inducing T-cell exhaustion, we used imiquimod-stimulated (IMQDC) bone marrow-derived DCs (BMDCs) pulsed with or without the whole CT-26 tumor antigen (Ag) as a therapeutic agent against CT-26 tumors in vivo and in vitro. Here, TYMP is linked to neoplasm.